Reply to letter to editor concerning “tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials”

El-Wui Loha Cochrane Taiwan, Taipei Medical University, Taipei, Taiwan;b Center for Evidence-Based Health Care, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan;c Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

https://orcid.org/0000-0001-9346-6886

Ka-Wai Tama Cochrane Taiwan, Taipei Medical University, Taipei, Taiwan;b Center for Evidence-Based Health Care, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan;d Division of General Surgery, Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan;e Division of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, New Taipei City, TaiwanCorrespondence[email protected]

https://orcid.org/0000-0002-1994-834X

References

Su J, Fu Y, Wang M, et al. The pathogenesis and treatment differences between differentiated thyroid carcinoma and medullary thyroid carcinoma. Curr Med Res Opin. 2022;6:1–2.
Google Scholar
Liu JW, Chen C, Loh EW, et al. Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2018;34(5):795–803.
PubMed Web of Science ®Google Scholar
Kiyota N, Schlumberger M, Muro K, et al. Subgroup analysis of Japanese patients in a phase 3 study of Lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci. 2015;106(12):1714–1721.
PubMed Web of Science ®Google Scholar
Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–630.
PubMed Web of Science ®Google Scholar
Hunter JE, Schmidt FL. Fixed effects vs. random effects meta‐analysis models: implications for cumulative research knowledge. Int J Sel Assess. 2000;8(4):275–292.
Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Reply to letter to editor concerning “tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials”

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Reply to letter to editor concerning “tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials”

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date